09.13.18
Particle Sciences has announced the appointment of Dr. Robert Lee to president.
With a decade of service at the company, most recently as executive vice president of Pharmaceutical Services, and 17 years overall, Dr. Lee has been instrumental in the business’ growth and current position as a leading CDMO for complex drug products. His new role as president will enable him to continue to increase Particle Sciences’ growth by expanding the company’s technical capabilities while continuing its commitment to executing client projects on time and budget.
Since Particle Sciences was acquired by Lubrizol in 2015, the business has experienced continued growth. Average sales have increased by 20 percent year-over-year since the acquisition due in part to the development and manufacturing of insoluble, sterile and highly potent drug products. The company is currently investing in its complex drug manufacturing capabilities and is due to announce the opening of a state-of-the-art Drug Product manufacturing facility in the coming months, part of an overall $60 million LifeSciences business unit investment.
This new space will leverage the company's knowledge of complex formulations and drug product manufacturing, accommodating both sterile and non-sterile finished drug products, such as ophthalmics, drug-device combination products, injectables, micro- and nanoparticulate formulations and lyophilized drugs.
Barbara Morgan, general manager of Particle Sciences states, “Robert comes to this position with extensive industry experience and company knowledge and takes the helm at a very exciting time for the business. As we further expand our facilities and strengthen our service offering, we look forward to continued success as the Particle Sciences’ team works under Robert’s leadership.”
With a decade of service at the company, most recently as executive vice president of Pharmaceutical Services, and 17 years overall, Dr. Lee has been instrumental in the business’ growth and current position as a leading CDMO for complex drug products. His new role as president will enable him to continue to increase Particle Sciences’ growth by expanding the company’s technical capabilities while continuing its commitment to executing client projects on time and budget.
Since Particle Sciences was acquired by Lubrizol in 2015, the business has experienced continued growth. Average sales have increased by 20 percent year-over-year since the acquisition due in part to the development and manufacturing of insoluble, sterile and highly potent drug products. The company is currently investing in its complex drug manufacturing capabilities and is due to announce the opening of a state-of-the-art Drug Product manufacturing facility in the coming months, part of an overall $60 million LifeSciences business unit investment.
This new space will leverage the company's knowledge of complex formulations and drug product manufacturing, accommodating both sterile and non-sterile finished drug products, such as ophthalmics, drug-device combination products, injectables, micro- and nanoparticulate formulations and lyophilized drugs.
Barbara Morgan, general manager of Particle Sciences states, “Robert comes to this position with extensive industry experience and company knowledge and takes the helm at a very exciting time for the business. As we further expand our facilities and strengthen our service offering, we look forward to continued success as the Particle Sciences’ team works under Robert’s leadership.”
